Presidio Pharmaceuticals Obtains $21,827,981 Series D Funding Round

  • Feed Type
  • Date
    6/16/2014
  • Company Name
    Presidio Pharmaceuticals
  • Mailing Address
    1700 Owens Street San Francisco, CA 94158 USA
  • Company Description
    Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections.
  • Website
    http://www.presidiopharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $21,827,981
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor

Trending on Xconomy